To explore the pathological basis, molecular mechanisms, risk factors, monitoring approaches, and treatment strategies related to anthracycline-induced cardiorenal toxicity, emphasizing their interrelation.
Key Findings:
Anthracyclines are associated with significant cardiotoxicity and nephrotoxicity, with incidence rates varying widely, from 5% to 48% for cardiotoxicity and 12% to 18% for nephrotoxicity.
Cardiac and renal injuries are interrelated, creating a cardiorenal vicious cycle that complicates treatment.
Current cardioprotective strategies, such as dexrazoxane, have limited effects on renal protection.
There is a lack of standardized guidelines for monitoring and managing anthracycline-induced cardiorenal toxicity, impacting clinical outcomes.
Interpretation:
A comprehensive understanding of the mechanisms behind anthracycline-induced cardiorenal toxicity is essential for optimizing therapy and improving patient outcomes in clinical practice.
Limitations:
Limited large-scale epidemiological studies focusing on renal toxicity as a primary endpoint, which hampers understanding of its clinical significance.
Existing studies often emphasize cardiotoxicity over nephrotoxicity, leading to a gap in knowledge.
Conclusion:
There is an urgent need for effective monitoring and intervention strategies to mitigate the risks of cardiorenal toxicity in patients receiving anthracycline therapy, highlighting the importance of addressing both cardiac and renal aspects.
